The anti-nausea drug Zofran (ondansetron), which was approved to treat nausea and vomiting in post-surgical and cancer patients, has been prescribed off-label to pregnant women to treat morning sickness. It has not been approved for use in pregnant women, and has been linked to doubled risks of heart defects and serious illness in newborns.
The Zofran Litigation Group educates members about Zofran; provides members with clients suffering from related conditions with work product and documents, including pleadings, discovery, and legal research; and provides a venue for networking and brainstorming ideas about how to best represent clients.
The Litigation Group provides member benefits such as a document library, including pleadings, discovery, legal research. and medical literature; a members-only list server; educational programs; and closed members-only meetings. The Group also hosts webinars, seminars in advance of JPML hearings, and other programs.
This Litigation Group was started in February 2015.